Lowell Schmeltz, MD
Endocrinology, Diabetes & Metabolism · Farmington Hills, MINPI 1538112917
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,124,267 of the $1,301,480 with a category attached, or 86.4%. 55 manufacturers reported payments, led by Lilly USA, LLC at 49.4% of the total. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,382 payments — averaging $546.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$643K
- Novo Nordisk$249K
- Sanofi-aventis U.S. LLC$110K
- Abbott$73K
- Dexcom, Inc.$60K
- Boehringer Ingelheim$57K
- plus $110K from 49 others
Across 220 payments — averaging $4396.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$550K
- Abbott$180K
- Siemens Medical Solutions USA, Inc.$108K
- Roche Diagnostics Operations, Inc.$83K
- Sanofi US Services Inc.$46K
What the payments were for
- Consulting fees$62,8885%
- Speaking & faculty fees$1,124,26786%
- Travel & lodging$79,1776%
- Food & beverage$35,0503%
- Education$480%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$255,964
- TRULICITY$201,598
- JARDIANCE$146,492
- TZIELD$130,527
- Ozempic$117,726
- RYBELSUS$77,310
- HUMULIN$40,250
- FREESTYLE LIBRE 3$36,327
- DEXCOM G7 GSS (161)$35,445
- Tresiba$31,077
- DEXCOM G6 TRANSMITTER$19,589
- t:slim X2 Insulin Pump with Control-IQ$17,694
- Kerendia$17,095
- FreeStyle Libre Pro$13,706
- FreeStyle Libre$12,381
- STEGLATRO$9,346
- FreeStyle Libre 2$9,138
- GVOKE PFS$8,149
- DEXCOM STELO GLUCOSE BIOSENSOR$5,668
- Xultophy 100/3.6$4,772
How this compares
$1,301,480 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 376 | $575,100 |
| JardianceEmpagliflozin | 234 | $315,110 |
| OzempicSemaglutide | 50 | $89,742 |
| TrulicityDulaglutide | 35 | $67,954 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $67,425 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $65,223 |
| Tresiba Flextouch U-100Insulin Degludec | 88 | $64,461 |
| FarxigaDapagliflozin Propanediol | 35 | $47,533 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $36,671 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 184 | $33,846 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $31,253 |
| Novolog FlexpenInsulin Aspart | 58 | $28,640 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $28,498 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $23,568 |
| NovologInsulin Aspart | 32 | $15,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $643,192 | $653,462437 claims |
| Boehringer IngelheimJardiance | $56,580 | $315,110234 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $249,313 | $118,82795 claims |
| AstraZenecaFarxiga | $490 | $47,53335 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $314 | $11,131864 claims |
| AbbVieSynthroid | $5,296 | $7,51682 claims |
| Sanofi-aventis U.S. LLCLantus | $109,571 | $2,52117 claims |
| PfizerLevoxyl | $189 | $1,99046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Farmington Hills
- Gary EdelsonFarmington Hills$503K
- Jacob MoeFarmington Hills$7K
- George GrunbergerBloomfield Hills$931K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
- Kara HoisingtonLansing$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.